Guillain-Barré Syndrome: Etiology, Pathogenesis, and Clinical Features

Etiology

Guillain-Barré syndrome is an autoimmune polyradiculoneuropathy triggered by preceding infections in approximately two-thirds of cases, with Campylobacter jejuni being the single most important pathogen worldwide 1, 2
Campylobacter jejuni is the most frequently identified trigger globally, accounting for 30-32% of cases in most regions and up to 60-70% in some areas 3
Respiratory infections are the most common antecedent events (22-53% of cases) in Europe, North America, South America, and parts of Asia, and even more common in pediatric cases (50-70%) 3
Gastroenteritis is the most frequent preceding event in some regions like India and Bangladesh (36-47%) 3

The fundamental mechanism is molecular mimicry between microbial surface components and peripheral nerve structures, triggering cross-reactive antibodies that damage myelin or axons 4, 3
C. jejuni-related GBS: Structural similarities between C. jejuni lipo-oligosaccharides and human nerve gangliosides (GM1, GM1b, GD1a, GalNAc-GD1a) result in cross-reactive antibodies that activate complement and damage nerves 4

GBS typically presents with rapidly progressive bilateral weakness beginning in the legs and ascending to the arms and cranial muscles, with most patients reaching maximum disability within 2 weeks 2, 5
Progressive weakness: Bilateral limb weakness that progresses over days to 4 weeks maximum 2
Sensory symptoms: Sensory signs typically accompany motor weakness 2
Areflexia: Loss of deep tendon reflexes is characteristic 1
Temporal profile: Most patients reach maximum disability within 2 weeks; if maximum disability occurs within 24 hours or after 4 weeks, consider alternative diagnoses 5

Male sex: Men are more frequently affected than women 2
Increasing age: Incidence increases with age, though all age groups can be affected 2
Advanced age: Associated with higher mortality and poorer outcomes 6
Regional infection patterns: Geographic differences in clinical phenotypes correlate with rates of preceding infections 4, 3
AIDP predominance: 83-90% of GBS cases in Europe and North America 3
Axonal forms: More common in Asia, particularly where C. jejuni infection is prevalent 3
Severity correlation: In countries where C. jejuni is more common, approximately 80% present with severe GBS (disability score >2) compared to 40-60% in AIDP-predominant regions 3

Only 1 in 1,000-5,000 patients with C. jejuni infection develop GBS within the subsequent 2 months, highlighting that infection alone is insufficient 7
Not all C. jejuni strains possess the carbohydrate mimicry structures required to trigger cross-reactive antibodies—this strain-specific variation is a critical determinant 7
Host genetic factors significantly influence susceptibility, particularly polymorphisms in the TNF gene and MBL2 gene that affect immune response activation 7

The temporal relationship matters: GBS typically develops 3-30 days after the infectious illness, with most patients reaching maximum disability within 2 weeks of neurologic symptom onset 8